Read More Pharma Industry News Why Seaport’s U.S. IPO filing matters now for neuropsychiatric drug development and biotech capital markets Seaport Therapeutics has filed for a U.S. IPO. Read how its neuropsychiatry pipeline could test biotech investor appetite in 2026. byPallavi MadhirajuApril 11, 2026